Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis

• Main Authors: Wei Kang (Author), Kuan Peng (Author), Vincent K.C. Yan (Author), Daoud Al-Badriyeh (Author), Shing Fung Lee (Author), Hei Hang Edmund Yiu (Author), Yue Wei (Author), Silvia T. H. Li (Author), Xuxiao Ye (Author), Aya El Helali (Author), Ka On Lam (Author), Victor H. F. Lee (Author), Ian C. K. Wong (Author), Esther W. Chan (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Direct oral anticoagulants (DOACs) have demonstrated clinical benefits and better patient adherence over low-molecular-weight heparin (LMWH) in treating patients with cancer-associated venous thrombosis (CAT). We aimed to compare the cost-effectiveness of DOACs against LMWH in patients wi...